NASDAQ:LGND - Ligand Pharmaceuticals Stock Price, Forecast & News

Ligand Pharmaceuticals trades on the NASDAQ under the ticker symbol "LGND."

Ligand Pharmaceuticals Inc. (NASDAQ:LGND) issued its earnings results on Tuesday, November, 5th. The biotechnology company reported $0.49 earnings per share for the quarter, missing the consensus estimate of $0.61 by $0.12. The biotechnology company had revenue of $24.81 million for the quarter, compared to analysts' expectations of $22.49 million. Ligand Pharmaceuticals had a net margin of 388.69% and a return on equity of 7.47%. The company's revenue was down 45.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.32 earnings per share. View Ligand Pharmaceuticals' Earnings History.

Ligand Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, February 6th 2020. View Earnings Estimates for Ligand Pharmaceuticals.

Ligand Pharmaceuticals will be holding an earnings conference call on Thursday, February 6th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Ligand Pharmaceuticals updated its FY19 earnings guidance on Tuesday, November, 5th. The company provided earnings per share guidance of ~$3.00 for the period, compared to the Thomson Reuters consensus estimate of $3.25. The company issued revenue guidance of ~$118 million, compared to the consensus revenue estimate of $119.01 million.

4 brokerages have issued 12 month price targets for Ligand Pharmaceuticals' stock. Their forecasts range from $132.00 to $214.00. On average, they anticipate Ligand Pharmaceuticals' stock price to reach $166.50 in the next twelve months. This suggests a possible upside of 82.9% from the stock's current price. View Analyst Price Targets for Ligand Pharmaceuticals.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ligand Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ligand Pharmaceuticals.

Media coverage about LGND stock has been trending positive recently, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Ligand Pharmaceuticals earned a news sentiment score of 3.0 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the near future. View News Stories for Ligand Pharmaceuticals.

Some companies that are related to Ligand Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Ligand Pharmaceuticals investors own include Jazz Pharmaceuticals (JAZZ), NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), Illumina (ILMN), Netflix (NFLX), Baidu (BIDU), Gilead Sciences (GILD), salesforce.com (CRM) and Intel (INTC).

Ligand Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Woodstock Corp (0.41%), Summit Creek Advisors LLC (0.40%), Louisiana State Employees Retirement System (0.02%), State of Alaska Department of Revenue (0.02%) and Nisa Investment Advisors LLC (0.01%). Company insiders that own Ligand Pharmaceuticals stock include Charles S Berkman, Jason Aryeh, John L Higgins, John L Lamattina, John W Kozarich, Matthew E Korenberg, Matthew W Foehr, Stephen L Sabba, Sunil Patel and Todd C Davis. View Institutional Ownership Trends for Ligand Pharmaceuticals.

LGND stock was sold by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, Louisiana State Employees Retirement System and Summit Creek Advisors LLC. View Insider Buying and Selling for Ligand Pharmaceuticals.

LGND stock was acquired by a variety of institutional investors in the last quarter, including Woodstock Corp and Nisa Investment Advisors LLC. Company insiders that have bought Ligand Pharmaceuticals stock in the last two years include Jason Aryeh, John L Higgins and Sunil Patel. View Insider Buying and Selling for Ligand Pharmaceuticals.

Shares of LGND can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of LGND stock can currently be purchased for approximately $91.03.

Ligand Pharmaceuticals has a market capitalization of $1.60 billion and generates $251.45 million in revenue each year. The biotechnology company earns $143.32 million in net income (profit) each year or $6.28 on an earnings per share basis. Ligand Pharmaceuticals employs 116 workers across the globe.View Additional Information About Ligand Pharmaceuticals.

The official website for Ligand Pharmaceuticals is http://www.ligand.com/.

Ligand Pharmaceuticals' mailing address is 3911 SORRENTO VALLEY BLVD SUITE 110, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-550-7500 or via email at [email protected]